



## **Accera, Inc. Completes \$35 Million Series C Financing**

**Broomfield, Colo., November 10, 2008** – Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced it has recently closed a Series C financing round of \$35 million (€27 million), led by Inventages Venture Capital SA. Proceeds of this financing will be used to begin sales and marketing of the company's lead product, Axona™ (previously known as Ketasyn), which is scheduled to launch in the United States in the first quarter of 2009.

Inventages was joined in this round by San Diego-based POSCO BioVentures and other previous private investors. Inventages and POSCO participated in the Company's Series A and B rounds.

Steve Orndorff, Ph.D., Accera's founder and CEO, said, "Closing this transaction in the current difficult financial environment is a testament to the confidence of our investors in the Accera organization and the potential of Axona".

Wolfgang Reichenberger, Ph.D., general partner, Inventages WHealth Management Inc. and IVC Americas SA and a member of Accera's Board of Directors, expressed enthusiasm about the commercial direction of the company and the upcoming launch of Axona. "Metabolic intervention is a new approach to neurodegenerative diseases, and Accera is a clear leader. We are pleased to support the commercialization of Axona as the lead product from this novel technology platform," Reichenberger said.

### **About Accera, Inc.**

Accera, Inc., a privately held biotechnology company, discovers and develops breakthroughs in central nervous systems disorders. Accera's novel approaches positively impact patients with neurodegenerative disorders who are in need of effective, well-tolerated therapies. Through its proprietary scientific platform, Accera is developing products that address metabolic deficiencies by providing an alternative energy source for the brain. For more information, visit [www.accerapharma.com](http://www.accerapharma.com).

###

### **Contacts**

#### Media:

Kelly McKenna  
MS&L Worldwide  
(415) 293-2808  
[Kelly.mckenna@msslworldwide.com](mailto:Kelly.mckenna@msslworldwide.com)

#### Investors:

Greg Kading  
Vice President, Finance  
Accera, Inc.  
(303) 999-3704  
[gkading@accera.com](mailto:gkading@accera.com)